Navigation Links
European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane
Date:9/28/2010

MALVERN, Pa., Sept. 28 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that more than half of all European inpatients who receive anticoagulants during their hospital stay are administered Sanofi-Aventis's Clexane (marketed as Lovenox in the U.S. and France).

The new audit entitled The European Hospital Anticoagulant Market Guide is a comprehensive source for anticoagulant use in European hospitals. Released quarterly, the audit contains detailed clinical data from thousands of hospitalized patients receiving anticoagulants. Survey results are projected to the national level for France, Germany, Italy, Spain and the United Kingdom.

The audit also reveals that surgical venous thromboembolism (VTE) primary prophylaxis accounts for the largest share of inpatient anticoagulant use at 48 percent of all inpatients. However, non-surgical VTE and stroke prophylaxis remains a key area of growth opportunity for companies marketing and developing anticoagulant agents.

The European Hospital Anticoagulant Market Guide is designed to help biopharmaceutical companies quantify targeted patient segments, better understand treatment practices and customers, size commercial opportunity and formulate clinical development strategy.

Besides Clexane, Boehringer Ingelheim's Pradaxa, Bayer's Xarelto and all other anticoagulants used in European hospitals are tracked in this audit.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
3. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
4. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
5. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
6. European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years
7. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
8. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
9. Sunridge Schedules European Meetings
10. European Patent Office Upholds GlideScope® Video Laryngoscope Patent
11. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
Breaking Medicine News(10 mins):